These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 340950)

  • 1. Morphologic and functional evidence for release of mast-cell products in bullous pemphigoid.
    Wintroub BU; Mihm MC; Goetzl EJ; Soter NA; Austen KF
    N Engl J Med; 1978 Feb; 298(8):417-21. PubMed ID: 340950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IgE in the serum and on mast cells in bullous pemphigoid.
    Nieboer C; van Leeuwen HJ
    Arch Dermatol; 1980 May; 116(5):555-6. PubMed ID: 6990870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linear dermo-epidermal IgA deposition in bullous pemphigoid.
    van Joost T; Faber WR; Westerhof W; de Mari F
    Acta Derm Venereol; 1979; 59(5):463-5. PubMed ID: 93374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A child with antibodies targeting both linear IgA bullous dermatosis and bullous pemphigoid antigens.
    Darling TN; Cardenas AA; Beard JS; Sau P; Yee CL; Zone JJ; Yancey KB
    Arch Dermatol; 1995 Dec; 131(12):1438-42. PubMed ID: 7492135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The complement system in bullous pemphigoid. III. Fixation of C1q and C4 by pemphigoid antibody.
    Jordon RE; Nordby JM; Milstein H
    J Lab Clin Med; 1975 Nov; 86(5):733-40. PubMed ID: 1102620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel immune-mediated subepidermal bullous dermatosis characterized by IgG autoantibodies to a lower lamina lucida component.
    Chan LS; Cooper KD
    Arch Dermatol; 1994 Mar; 130(3):343-7. PubMed ID: 8129413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An eosinophil chemotactic factor present in blister fluids of bullous pemphigoid patients.
    Baba T; Sonozaki H; Seki K; Uchiyama M; Ikesawa Y; Toriisu M
    J Immunol; 1976 Jan; 116(1):112-6. PubMed ID: 1107422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Psoriasis and bullous pemphigoid].
    Bork K
    Hautarzt; 1987 Jun; 38(6):348-51. PubMed ID: 3308771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cicatricial pemphigoid of Brunsting-Perry. Immunofluorescent studies.
    Michel B; Bean SF; Chorzelski T; Fedele CF
    Arch Dermatol; 1977 Oct; 113(10):1403-5. PubMed ID: 334084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Herpes gestationis. Immunopathologic studies in mother and child].
    Schöpf E; Seelig HP; Clorius R; Sheikh M; Bersch A
    Hautarzt; 1976 Oct; 27(10):481-7. PubMed ID: 791898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential role of interleukin-17 in the pathogenesis of bullous pemphigoid.
    Toosi S; Bystryn JC
    Med Hypotheses; 2010 Apr; 74(4):727-8. PubMed ID: 19945799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional evidence for complement-activating immune complexes in the skin of patients with bullous pemphigoid.
    Gammon WR; Merritt CC; Lewis DM; Sams WM; Wheeler CE; Carlo JR
    J Invest Dermatol; 1982 Jan; 78(1):52-7. PubMed ID: 7033396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunologic phenomena in the skin of patients with pemphigoid in relation to the pathologic process].
    Torzecka JD; Lutowiecka-Wranicz A; Sysa-Jedrzejowska A; Waszczykowska E; Dziankowska-Bartkowiak B
    Przegl Dermatol; 1988; 75(4):266-71. PubMed ID: 3070636
    [No Abstract]   [Full Text] [Related]  

  • 14. Induction of leukocyte adherence at the basement membrane zone with subsequent activation of their metabolic pathway by pemphigoid antibodies and complement.
    Iwatsuki K; Tagami H; Yamada M
    Acta Derm Venereol; 1983; 63(4):290-5. PubMed ID: 6195859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of lesion production in pemphigus and pemphigoid.
    Sams WM; Gammon WR
    J Am Acad Dermatol; 1982 Apr; 6(4 Pt 1):431-52. PubMed ID: 7042774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orf-induced immunobullous disease: A distinct autoimmune blistering disorder.
    White KP; Zedek DC; White WL; Simpson EL; Hester E; Morrison L; Lazarova Z; Liu D; Scagliarini A; Kurtz SE; White CR; Yancey KB; Blauvelt A
    J Am Acad Dermatol; 2008 Jan; 58(1):49-55. PubMed ID: 17919774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mast cell-dependent effector pathways and cutaneous bullous disorders.
    Wintroub BU; Mihm MC
    Springer Semin Immunopathol; 1981 Jun; 4(1):65-72. PubMed ID: 7022723
    [No Abstract]   [Full Text] [Related]  

  • 18. The predominance of IgG4 in prodromal bullous pemphigoid.
    Lamb PM; Patton T; Deng JS
    Int J Dermatol; 2008 Feb; 47(2):150-3. PubMed ID: 18211485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coexistence of bullous pemphigoid and systemic lupus erythematosus.
    Kumar V; Binder WL; Schotland E; Beutner EH; Chorzelski TP
    Arch Dermatol; 1978 Aug; 114(8):1187-90. PubMed ID: 354534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Childhood localized vulvar pemphigoid is a true variant of bullous pemphigoid.
    Saad RW; Domloge-Hultsch N; Yancey KB; Benson PM; James WD
    Arch Dermatol; 1992 Jun; 128(6):807-10. PubMed ID: 1599268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.